Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant vs Tamoxifen in Cyclin D1+ ER+ Breast Cancer
NCT02936206Phase 1Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Change in Ki67 Cell Percentage at 2 weeks. Started Oct 2016; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02936206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936206.